Main navigation

• Home
• About us
• Medicines
• Research
• Careers
• Responsibility
• Partnering
• Media
• Investors
  • Directors' shareholdings
  • Financial calendar
  • Annual reports
  • Financial highlights
  • Strategy
  • Investor contacts
  • Corporate governance
  • Shareholder information
  • Investor tools
  • SEC filings
  • Financial results
  • Presentations & webcasts
  • FAQs

You are here

• Home

• Investor relations

• Latest news collapse

  • 19 November 2009 AstraZeneca Submits US New Drug Application for Brilinta (Ticagrelor), an Investigational Antiplatelet Agent

    AstraZeneca today announced it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA, pending approval from the FDA.

  more news

  • previous
  • • 1
    • 2
    • 3
    • 4
    • 5
  • next

  Research & Development collapse

  We focus our research on six disease areas where we believe our skills and experience can make the most difference.

  • Read about our disease area focus
  • Read about our pipeline progress
  • Review our pipeline summary

  Share price tools collapse

  • Interactive stock charts
  • Share holding calculator
  • Share price look-up
  • Share price history

• Annual Report 2008 collapse

  • Online annual report
  • Order a printed copy

  Latest presentation collapse

  November 2009

  • Investor Relations general presentation (PDF 3 Mb)

  • Other presentations

  Financial results collapse

  Third Quarter & Nine Months results 2009 announced Thursday, 29 October 2009.

  • View details of the event
  • View financial calendar

  Managing your shares expand

  Currency Guidance 2009 collapse

  • View 2009 currency guidance

Not signed in

Page tools

• Print
• Bookmark this page

Share price